Samuel Odarkwei Blankson

Mr. Samuel Odarkwei Blankson

West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Legon, Accra, Ghana
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
FAFelix Ansah
Felix Ansah
JSJonathan Suurbaar
Jonathan Suurbaar
DDDerrick Darko
Derrick Darko
NANsoh G. Anabire
Nsoh G. Anabire
SBSamuel Odarkwei Blankson
Samuel Odarkwei Blankson
YAYaw Aniweh
Yaw Aniweh
Plasmodium malariae and Plasmodium ovale are increasingly gaining public health attention as the global transmission of falciparum malaria is decreasing. However, the absence of reliable Plasmodium species-specific detection tools has hampered accurate diagnosis of these minor Plasmodium species. In this study, SYBR Green–based real-time PCR assays were developed for the detection of P. malariae and P. ovale using cooperative primers that significantly limit the formation and propagation of primers-dimers. Both the P. malariae and P. ovale cooperative primer-based assays had at least 10-fold lower detection limit compared with the corresponding conventional primer-based assays. More important, the cooperative primer-based assays were evaluated in a cross-sectional study using 560 samples obtained from two health facilities in Ghana. The prevalence rates of P. malariae and P. ovale among the combined study population were 18.6% (104/560) and 5.5% (31/560), respectively. Among the Plasmodium-positive cases, P. malariae and P. ovale mono-infections were 3.6% (18/499) and 1.0% (5/499), respectively, with the remaining being co-infections with Plasmodium falciparum. The study demonstrates the public health importance of including detection tools with lower detection limits in routine diagnosis and surveillance of nonfalciparum species. This will be necessary for comprehensively assessing the effectiveness of malaria interventions and control measures aimed toward global malaria elimination.

18 February 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
BTBernard Tornyigah
Bernard Tornyigah
SBSamuel Odarkwei Blankson
Samuel Odarkwei Blankson
RARafiou Adamou
Rafiou Adamou
AMAzizath Moussiliou
Azizath Moussiliou
LRLauriane Rietmeyer
Lauriane Rietmeyer
Rachida TaharRachida Tahar
Rachida Tahar
Malaria-related deaths could be prevented if powerful diagnostic and reliable prognostic biomarkers were available to allow rapid prediction of the clinical severity allowing adequate treatment. Using quantitative ELISA, we assessed the plasma concentrations of Procalcitonin, Pentraxine-3, Ang-2, sTie-2, suPAR, sEPCR and sICAM-1 in a cohort of Beninese children with malaria to investigate their potential association with clinical manifestations of malaria. We found that all molecules showed higher levels in children with severe or cerebral malaria compared to those with uncomplicated malaria (p-value < 0.005). Plasma concentrations of Pentraxine-3, Procalcitonin, Ang-2 and the soluble receptors were significantly higher in children with coma as defined by a Blantyre Coma Score < 3 (p < 0.001 for Pentraxine-3, suPAR, and sTie-2, p = 0.004 for PCT, p = 0.005 for sICAM-1, p = 0.04 for Ang-2). Moreover, except for the PCT level, the concentrations of Pentraxine-3, suPAR, sEPCR, sICAM-1, sTie-2 and Ang-2 were higher among children who died from severe malaria compared to those who survived (p = 0.037, p = 0.035, p < 0.0001, p= 0.0008, p = 0.01 and p = 0.02, respectively). These findings indicate the ability of these molecules to accurately discriminate among clinical manifestations of malaria, thus, they might be potentially useful for the early prognostic of severe and fatal malaria, and to improve management of severe cases.

4 April 2022 in Malaria Journal
Verified
Journal Article
Open access
PDF file
SBSamuel Odarkwei Blankson
Samuel Odarkwei Blankson
DDDanielle Seri Dadjé
Danielle Seri Dadjé
NTNadjla Traikia
Nadjla Traikia
MAMaroufou J. Alao
Maroufou J. Alao
SASerge Ayivi
Serge Ayivi
RTRachida Tahar
Rachida Tahar
Background: Cytoadhesion and sequestration of Plasmodium falciparum infected red blood cells (iRBC) in the microvasculature of vital organs are a major cause of malaria pathology. Several studies have provided evidence on the implication of the human host intercellular adhesion molecule-1 (ICAM-1) as a major receptor for iRBCs binding to P. falciparum erythrocyte membrane protein 1 (PfEMP1) in the development of severe and cerebral malaria. The genetic polymorphism K29M in the immunoglobulin-like domain of ICAM-1, known as ICAM-1Kilifi, has been associated with either increased or decreased risk of developing cerebral malaria. Methods: To provide more conclusive results, the genetic polymorphism of ICAM-1Kilifi was assessed by PCR and sequencing in blood samples from 215 Beninese children who presented with either mild or severe malaria including cerebral malaria. Results and conclusions: The results showed that in this cohort of Beninese children, the ICAM-1kilifi variant is present at the frequencies of 0.27, similar to the frequency observed in other African countries. This ICAM-1kilifi variant was not associated with disease severity in agreement with other findings from the Gambia, Tanzania, Malawi, Gabon, and Thailand, suggesting no evidence of a direct link between this polymorphism and the pathogenesis of severe and cerebral malaria.

31 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
SBSamuel Odarkwei Blankson
Samuel Odarkwei Blankson
LRLauriane Rietmeyer
Lauriane Rietmeyer
PTPatrick Tettey
Patrick Tettey
LDLiliane Beatrice Dikroh
Liliane Beatrice Dikroh
BTBernard Tornyigah
Bernard Tornyigah
Rachida TaharRachida Tahar
Rachida Tahar
Among the barriers to accessing adequate treatment and high-level monitoring for malaria febrile patients is the lack of effective prognostic markers. Neopterin, which is a marker of monocyte/macrophage activation, was found have increased during severe malaria. In this study, we used quantitative ELISA in order to assess the levels of plasma soluble neopterin in 151 patients from a cohort of Beninese children with severe malaria. We evaluated the prognostic accuracy of this molecule in order to predict the outcome of the disease. Our results show that neopterin levels were not significantly different between patients with different forms of severe malaria, including severe non-cerebral malaria (SNCM) and cerebral malaria (CM). However, the levels of this molecule were found to be higher in patients with severe malarial anemia (SMA) among both CM and SNCM cases (p-value = 0.02). Additionally, the levels of this molecule were found to be higher in patients who died from these pathologies compared to those who survived among the two clinical groups (p-value < 0.0001) and within the same group (p-value < 0.0001 for the CM group, p-value = 0.0046 for the SNCM group). The AUC-ROC for fatality among all the severe cases was 0.77 with a 95%CI of (0.69–0.85). These results suggest that plasma neopterin levels constitute a potential biomarker for predicting fatality among severe falciparum malaria patients.

8 April 2026
Verified
Thesis
Closed access
SBSamuel Odarkwei Blankson
Samuel Odarkwei Blankson
Comprendre la pathogénèse du paludisme grave : le rôle des marqueurs sérologiques et des vésicules extracellulaires dérivées du plasma: Le paludisme grave (PG) comprend les formes complexes de l'infection par Plasmodium falciparum, dont le neuropaludisme (NP) et constitue une cause majeure de mortalité, chez les enfants en Afrique subsaharienne. La physiopathologie du PG n'est pas totalement élucidée et le manque de test pronostiques et de traitements auxiliaires rendent sa prise en charge difficile. Ce travail explore les molécules sérologiques et le contenu bioactif des vésicules extracellulaires (VE) circulantes des patients atteints de différentes formes cliniques du paludisme comprenant le paludisme grave sans atteintes neurologique (PGSN), NP et le paludisme simple (PS) afin d'identifier des biomarqueurs pronostiques et d'améliorer la compréhension de la physiopathologie du PG et NP nécessaire pour découvrir de nouvelles voies thérapeutiques. Nous avons alors mesuré les niveaux d'Ang-2, Tie2, sEPCR, sICAM-1, Pentraxine 3 (PTX3), procalcitonine (PCT) et néoptérine afin d'évaluer leur potentiel à prédire la gravité et les issues de la maladie. Nos résultats montrent que les niveaux des molécules plasmatiques sont augmentés chez les patients atteints de PG par rapport aux patients avec un PS. La PCT et sTie2 produisent la meilleure performance diagnostique pour la gravité alors que sEPCR, néoptérine et sICAM-1 se démarquent comme marqueurs prédictifs de mortalité, tandis que PTX3 et sICAM-1 étaient les meilleurs marqueurs pronostiques pour le coma. Notre analyse des polymorphismes des gènes ICAM-1 et EPCR, supposés impliqués dans le PG et le NP pour déterminer leur association au NP et PGSN montrent l'absence d'association entre le variant kilifi ICAM-1 et la prédisposition au NP, suggérant que d'autres facteurs, comme les variants de PfEMP1 exprimés par le parasite et interagissant avec ICAM-1 pourraient jouer un rôle et expliquer les résultats contradictoires entre les études. Cependant, des niveaux plus élevés de sEPCR étaient associés à l'allèle G du polymorphisme rs867186 de l'EPCR, à une gravité accrue du paludisme et à des taux de mortalité plus élevés, confirmant l'intérêt du sEPCR comme marqueur pronostic de fatalité. L'analyse de 188 miARN humain et du protéome contenus dans les VE dérivées des plasmas de 5 patients par groupe clinique NP, PGSN et PS, révèle 14 miARN différentiellement exprimés, dont six peuvent constituer des biomarqueurs pour le prognostic des NP et PGSN. L'analyse bio-informatique KEGG a montré que ces miARN ciblent des gènes impliqués dans des voies contribuant à la gravité de la maladie. L'analyse protéomique a permis d'identifier 1 572 protéines, dont 86 d'origine parasitaire. 209 protéines étaient surexprimées chez les patients atteints de NP par rapport aux ceux atteints de PS et 107 protéines étaient dans le groupe de NP versus PGSN. Seulement 34 protéines étaient surexprimées dans le groupe PGSN comparés au PS. Les voies les plus enrichies dans le NP/PS incluaient les signalisations BAG2, FAT10, ubiquitination, alors que les voies ID1, phagocytose dépendante de Fc semblent plus enrichies dans la comparaison NP/PGSN. De plus, la signalisation nNOS dans les neurones, la dégradation de la citrulline et la signalisation IL-2 étaient très enrichies dans la comparaison PGSN/PS. L'analyse bio-informatique en interrogeant la base de données fonctions et pathologies a révélé l'implication des protéines surexprimées dans des processus tel que la mort cellulaire, la communication cellulaire, la cytoadherence, l'inflammation, la réponse immunitaire, Ce projet a permis d'identifier des biomarqueurs prometteurs, notamment des molécules sériques, des miARN et des protéines issues des VE circulantes, pour prédire le NP et le PGSN ainsi que leurs issues. Ces molécules pourraient également jouer un rôle dans la physiopathologie de ces conditions cliniques. Des études ultérieures sont nécessaires pour valider ces marqueurs à travers des recherches fonctionnelles et translationnelles.